跳至主要内容
临床试验/CTRI/2013/12/004252
CTRI/2013/12/004252
招募中
未知

A Study to Evaluate the Prevalence of Hypogonadism in Indian Males with Type 2 Diabetes Mellitus (DM).

MSD Pharmaceuticals Pvt Ltd0 个研究点目标入组 897 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Health Condition 1: null- Indian Males with Type 2 Diabetes Mellitus who may or may not be suffering with Hypogonadism.
发起方
MSD Pharmaceuticals Pvt Ltd
入组人数
897
状态
招募中
最后更新
4年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
4年前
研究类型
Observational

研究者

发起方
MSD Pharmaceuticals Pvt Ltd

入排标准

入选标准

  • 1\.Males between the age of 30 to 59 years (both inclusive), with a confirmed diagnosis of Type\-2 diabetes mellitus
  • 2\.Each subject must be willing to provide written informed consent

排除标准

  • 1\.Type 1 diabetes patients
  • 2\.Patients receiving testosterone replacement therapy
  • 3\.Patients suffering from any chronic liver disease, renal disease, advanced malignancy, debilitating diseases like tuberculosis, malabsorption, inflammatory bowel disease, pyrexia of unknown origin, AIDS, sickle cell disease, autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis
  • 4\.Patients with known causes of hypogonadism including:
  • o Hypergonadotropic hypogonadism or primary hypogonadism: testicular failure due to genetic disorders (e.g., Klinefelterâ??s syndrome), orchitis, trauma, castration, radiation, chemotherapy, or undescended testes
  • o Hypogonadotropic hypogonadism, central hypogonadism, or secondary hypogonadism: patients with gonadotropin deficiency or dysfunction as a result of disease or damage to the hypothalamic\-pituitary axis (e.g. Kallmannâ??s syndrome, tumour, trauma, radiation, sarcoidosis, or tuberculosis).
  • 5\.Patients on medications, or have taken medications in last 6 months, known to cause hypogonadal states like ketoconazole, anabolic steroids, corticosteroids, spironolactone, cimetidine, phenytoin, GnRH analogue, flutamide and narcotic addicts (heroin).
  • 6\.Patients having severe psychological symptoms
  • 7\.Patients currently enrolled in another clinical trial
  • 8\.Patients having any clinically significant condition or situation, other than the condition being studied that, in the opinion of the Investigator, would interfere with the study evaluations or optimal participation in the study.

结局指标

主要结局

未指定

相似试验